|
1
|
Holen KD, Klimstra DS, Hummer A, Gonen M,
Conlon K, Brennan M and Saltz LB: Clinical characteristics and
outcomes from an institutional series of acinar cell carcinoma of
the pancreas and related tumors. J Clin Oncol. 20:4673–4678. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Butturini G, Pisano M, Scarpa A, D'Onofrio
M, Auriemma A and Bassi C: Aggressive approach to acinar cell
carcinoma of the pancreas: A single-institution experience and a
literature review. Langenbecks Arch Surg. 396:363–369. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Klimstra DS, Heffess CS, Oertel JE and
Rosai J: Acinar cell carcinoma of the pancreas. A clinicopathologic
study of 28 cases. Am J Surg Pathol. 16:815–837. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Berner O: Subkutane fettgewebsnekrose.
Virchow Arch Path Anat. 193:510–518. 1908. View Article : Google Scholar
|
|
5
|
Wang Y, Wang S, Zhou X, Zhou H, Cui Y, Li
Q and Zhang L: Acinar cell carcinoma: A report of 19 cases with a
brief review of the literature. World J Surg Oncol. 14:1722016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schmidt CM, Matos JM, Bentrem DJ,
Talamonti MS, Lillemoe KD and Bilimoria KY: Acinar cell carcinoma
of the pancreas in the United States: Prognostic factors and
comparison to ductal adenocarcinoma. J Gastrointest Surg.
12:2078–2086. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Riediger C, Mayr M, Berger H, Becker K,
Dobritz M, Kleeff J and Friess H: Transarterial chemoembolization
of liver metastases as symptomatic therapy of lipase hypersecretion
syndrome. J Clin Oncol. 30:e209–e212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Simon M, Bioulac-Sage P, Trillaud H and
Blanc JF: FOLFOX regimen in pancreatic acinar cell carcinoma: Case
report and review of the literature. Acta Oncol. 51:403–405. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Williams JA: Regulation of acinar cell
function in the pancreas. Curr Opin Gastroenterol. 26:478–483.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abraham SC, Wu TT, Hruban RH, Lee JH, Yeo
CJ, Conlon K, Brennan M, Cameron JL and Klimstra DS: Genetic and
immunohistochemical analysis of pancreatic acinar cell carcinoma:
Frequent allelic loss on chromosome 11p and alterations in the
APC/beta-catenin pathway. Am J Pathol. 160:953–962. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schmid RM: Acinar-to-ductal metaplasia in
pancreatic cancer development. J Clin Invest. 109:1403–1404. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wagner M, Greten FR, Weber CK, Koschnick
S, Mattfeldt T, Deppert W, Kern H, Adler G and Schmid RM: A murine
tumor progression model for pancreatic cancer recapitulating the
genetic alterations of the human disease. Genes Dev. 15:286–293.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kopp JL, von Figura G, Mayes E, Liu FF,
Dubois CL, JP IV Morris, Pan FC, Akiyama H, Wright CV, Jensen K, et
al: Identification of Sox9-dependent acinar-to-ductal reprogramming
as the principal mechanism for initiation of pancreatic ductal
adenocarcinoma. Cancer Cell. 22:737–750. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vakiani E, Young RH, Carcangiu ML and
Klimstra DS: Acinar cell carcinoma of the pancreas metastatic to
the ovary: A report of 4 cases. Am J Surg Pathol. 32:1540–1545.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bogart MM, Milliken MC, Patterson JW and
Padgett JK: Pancreatic panniculitis associated with acinic cell
adenocarcinoma: A case report and review of the literature. Cutis.
80:289–294. 2007.PubMed/NCBI
|
|
16
|
Zundler S, Erber R, Agaimy A, Hartmann A,
Kiesewetter F, Strobel D, Neurath MF and Wildner D: Pancreatic
panniculitis in a patient with pancreatic-type acinar cell
carcinoma of the liver-case report and review of literature. BMC
Cancer. 16:1302016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Poruk KE, Gay DZ, Brown K, Mulvihill JD,
Boucher KM, Scaife CL, Firpo MA and Mulvihill SJ: The clinical
utility of CA 19–9 in pancreatic adenocarcinoma: Diagnostic and
prognostic updates. Curr Mol Med. 13:340–351. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Callata-Carhuapoma HR, Cour E Pato,
Garcia-Paredes B, Fernandez RM, Fernandez ML Mendoza, Fernandez AM,
De La Rosa CA, Lezama MJ Sotelo, Cabezas-Camarero S and Varela J
Sastre: Pancreatic acinar cell carcinoma with bilateral ovarian
metastases, panniculitis and polyarthritis treated with FOLFIRINOX
chemotherapy regimen. A case report and review of the literature.
Pancreatology. 15:440–444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chaudhary P, Ranjan G, Chaudhary A, Tiwari
AK and Arora MP: Acinar cell carcinoma: A rare pancreatic
malignancy. Clin Pract. 3:e182013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hall JC, Marlow LA, Mathias AC, Dawson LK,
Durham WF, Meshaw KA, Mullin RJ, Synnott AJ, Small DL, Krishna M,
et al: Novel patient-derived xenograft mouse model for pancreatic
acinar cell carcinoma demonstrates single agent activity of
oxaliplatin. J Transl Med. 14:1292016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
